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Dear Editor,
We thank you for the opportunity for commenting on the letter
by Ascerbi and co-workers. We feel the discussions surround-
ing fluorescence stimulating and interesting.
Our first experience with fluorescein was in 1991 when we
used fluorescein for marking perilesional edema in the cortical
cold lesion model [21]. We demonstrated fluorescein propa-
gating through the brain, driven by edema in the absence of
tumor. Thus, to us fluorescein has always been an excellent
edema marker.
Similarly, when first using fluorescein for brain tumor sur-
gery Moore et al. (1948) [17] noted that Bedematous brain
surrounding the tumor does fluoresce, but to a lesser degree
…^
Since then, investigators have taken up this technology on
and off, e.g., Kuoriwa and co-workers [11–13] for brain tumor
surgery. This group, incidentally, gave up fluorescein in 1999,
later pursuing ALA intensely [6–10, 15, 16, 22–24].
Currently, due to the availability of new filter systems, in-
vestigators have again adopted fluorescein for malignant glio-
mas. Anybody interested in the present use of this technique
should appraise footage from fluorescein surgery on the inter-
net (e.g., https://www.youtube.com/watch?v=mST6oPE69dE
and http://abcnews.go.com/Health/making-brain-tumors-
glow-saves-lives/story?id=17076243#) and draw their own
conclusions.
Nonetheless, filters will not change biology and fluorescein
will still only mark areas of the brain with blood–brain barrier
breakdown, which are somewhat but not strictly related to
tumor. Novel experimental work has confirmed fluorescein
staining to not be tumor-cell specific [5]. Extravasation and
propagation of fluorescein with edema will follow a distinc-
tive time course: after administration, levels will be high in
blood and perfused tissues, blood and CSF. With a half-life of
264 min, intravascular fluorescein will slowly subside, in the
mean time being extravasated with edema and travelling
through peritumoral tissue, raising the danger of staining
non-tumorous brain. Thus, the timing of surgery will be crit-
ical. The second problem arises from surgical tissue injury.
Any injury to the tissue will result in extravasation of fluores-
cein at the cut margin and any other areas of tissue injury.
Fluorescein in blood will stain such injured tissues. None of
the authors currently reporting on fluorescein discuss this
much, although these phenomena are clearly visible in images
from their publications (e.g., Fig. 1 in Ascerbi et al. 2014 [1];
Fig. 3e, f in Li et al. 2014 [14]; Fig. 3b in Schebesch et al. 2013
[20]; Fig. 1e in Rey-Dios and Cohen-Gadol et al. (2013) [19];
Fig. 7c in Diaz et al. 2015 [5]; Fig. 4b in Okuda et al. (2012)
[18]), where parts of the margin of the cavity and/or the sur-
rounding cortical tissues are stained after completion of tumor
removal. Why didn’t the authors continue resection in these
areas with clearly visible fluorescence?
Together, timing and dose appear to be essential, as Ascerbi
et al. acknowledge in their letter, but there does not appear to
be much consensus among current investigators regarding
these two aspects (Table 1). Ascerbi et al. suggest 5 mg/kg
to be administered i.v. after intubation, i.e., approximately 1 h
prior to dural opening. What happens when craniotomies take
longer or the tumor is large or when craniotomies are fast and
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the tumors small? In no publication so far is the temporal
aspect accounted for when regarding fluorescence in the later
stages of resection and its influence on diagnostic accuracy.
What we are simply saying here is that fluorescein is not
well investigated at this point and harbors a number of pitfalls
and hazards to justify too much enthusiasm. Frankly, surgeons
should be wary.
Surgical studies are tricky and the possibilities for advertent
or inadvertent bias numerous. Especially in studies on intra-
operative optical diagnosis, calculations of specificity and sen-
sitivity are highly influenced by sample location and number
of samples per patient. Thus, a high level of transparency and
control are necessary for such investigations, including exact
and objective description of how many biopsies were taken,
exactly from where and how a per-patient analysis compared
with a per-biopsy analysis (problematical mixing of depen-
dent and independent data) are handled. In addition, publica-
tions should strictly adhere to the STARD statement [3] for
studies on diagnostic accuracy. It is not apparent that this is
happening to a satisfactory extent in available reports on the
clinical use of fluorescein (Table 1). Clinical studies within a
proper GCP setting, including pre-defined study aims,
biometry and external monitoring would be more than wel-
come at this time.
Finally, the argument is frequently put forward [14, 20] that
fluorescein is cheaper than ALA and thus better. This percep-
tion is worrisome. If I were a patient with a brain tumor, I
would want something that is better or equally good. The price
would not be my worry.
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